Antibodies and immunoglobulin fusion proteins having modified effector functions and uses therefor
CA 2243986 A1 · Owner: Silver, Sandra · Inventors: Carson, Jerry; Gray, Gary S.; Silver, Sandra
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors which in turn can direct the , synthesis of the corresponding proteins in a variety of hosts particularly , eukaryotic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 3, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 3, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 3, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.